The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Open accessAbstract
As the incidence of Gram-negative bacterial infections for which few effective treatments remain increases, so does the contribution of drug-hydrolyzing β-lactamase enzymes to this serious clinical problem. This review highlights recent advances in β-lactamase inhibitors and focuses on agents with novel mechanisms of action against a wide range of enzymes. To this end, we review the β-lactamase inhibitors currently in clinical trials, select agents still in preclinical development, and older therapeutic approaches that are being revisited. Particular emphasis is placed on the activity of compounds at the forefront of the developmental pipeline, including the diazabicyclooctane inhibitors (avibactam and MK-7655) and the boronate RPX7009. With its novel reversible mechanism, avibactam stands to be the first new β-lactamase inhibitor brought into clinical use in the past 2 decades. Our discussion includes the importance of selecting the appropriate partner β-lactam and dosing regimens for these promising agents. This “renaissance” of β-lactamase inhibitors offers new hope in a world plagued by multidrug-resistant (MDR) Gram-negative bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,618
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,475
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367 · cited 1×
“As a class, these OXA -lactamases are not effectively inactivated by the available -lactam-type inhibitors; however, in vitro, concentrations of NaCl 100 mM inactivate most class D enzymes (103, 104).”
BackgroundAgents that increase the permeability of the outer membrane
Vaara, M. (1992) · Microbiological Reviews · doi:10.1128/mr.56.3.395-411.1992 · Cited by 1,879 · cited 1×
“In addition to chelating the zinc ions required for MBL hydrolysis, ion chelation may disrupt bacterial cell membranes and help disperse bacterial biofilms (94, 95).”
BackgroundThree Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Self-citationTackling antibiotic resistance
Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., Jacoby, G. A., Kishony, R., Kreiswirth, B. N., Kutter, E., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2693 · Cited by 1,062
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Jacoby, G. A., & Munoz-Price, L. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041359 · Cited by 787
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
Self-citationLauretti, L., Riccio, M. L., Mazzariol, A., Cornaglia, G., Amicosante, G., Fontana, R., & Rossolini, G. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1584 · Cited by 677
The emerging NDM carbapenemases
Nordmann, P., Poirel, L., Walsh, T. R., & Livermore, D. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.09.005 · Cited by 663
The Future of Antibiotics and Resistance
Spellberg, B., Bartlett, J. G., & Gilbert, D. N. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1215093 · Cited by 647
Diversity, Epidemiology, and Genetics of Class D β-Lactamases
Poirel, L., Naas, T., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-08 · Cited by 632
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Lee, K., Lim, Y. S., Yong, D., Yum, J. H., & Chong, Y. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4623-4629.2003 · Cited by 514
Metallo‐β‐lactamase structure and function
Palzkill, T. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06796.x · Cited by 505
Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in a Biofilm
Banin, E., Brady, K. M., & Greenberg, E. P. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.3.2064-2069.2006 · Cited by 473
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Self-citationDulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G. M., Myburgh, J., Paterson, D. L., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis856 · Cited by 394
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Durand-Réville, T. F., Lahiri, S., Thresher, J., Livchak, S., Gao, N., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485979 · Cited by 372
Detection of Pseudomonas aeruginosa Producing Metallo-β-Lactamases in a Large Centralized Laboratory
Pitout, J. D. D., Gregson, D. B., Poirel, L., McClure, J.-A., Le, P., & Church, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3129-3135.2005 · Cited by 331
New Delhi Metallo-β-Lactamase: Structural Insights into β-Lactam Recognition and Inhibition
King, D. T., Worrall, L. J., Gruninger, R., & Strynadka, N. C. J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303579d · Cited by 297
Héritier, C., Poirel, L., Lambert, T., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3198-3202.2005 · Cited by 272
Lamas, G. A., Goertz, C., Boineau, R., Mark, D. B., Rozema, T., Nahin, R. L., Lindblad, L., Lewis, E. F., Drisko, J., Lee, K. L., et al. (2013) · JAMA · doi:10.1001/jama.2013.2107 · Cited by 269
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Köhler, T., Michea-Hamzehpour, M., Epp, S. F., & Pechere, J.-C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.424 · Cited by 268
Livermore, D. M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., & Woodford, N. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00756-10 · Cited by 261
Naas, T., & Nordmann, P. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230112185101 · Cited by 250
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, K. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.026 · Cited by 241
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Laraki, N., Franceschini, N., Rossolini, G. M., Santucci, P., Meunier, C., de Pauw, E., Amicosante, G., Frère, J. M., & Galleni, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.902 · Cited by 233
Livermore, D. M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.012 · Cited by 232
Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J.-D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02247-12 · Cited by 230
Vazquez, J. A., González Patzán, L. D., Stricklin, D., Duttaroy, D. D., Kreidly, Z., Lipka, J., & Sable, C. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.748653 · Cited by 219
Fragment-based lead discovery grows up
Baker, M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3926 · Cited by 214
Metallo‐β‐Lactamases: A Class Apart
Bush, K. (1998) · Clinical Infectious Diseases · doi:10.1086/514922 · Cited by 205
In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor
Bonnefoy, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh358 · Cited by 185
Naas, T., & Nordmann, P. (1999) · PubMed · Cited by 183
Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-Lactamase
Papp-Wallace, K. M., Bethel, C. R., Distler, A. M., Kasuboski, C., Taracila, M., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00693-09 · Cited by 180
Self-citationAzap, Ö. K., Arslan, H., Şerefhanoğlu, K., Çolakoğlu, Ş., Erdoğan, H., Timurkaynak, F., & Senger, S. S. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02941.x · Cited by 180
Stachyra, T., Levasseur, P., Pechereau, M.-C., Girard, A.-M., Claudon, M., Miossec, C., & Black, M. T. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp197 · Cited by 180
Aktaş, Z., Kayacan, C., & Oncul, O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.012 · Cited by 169
Therapeutic Options for Infections with Enterobacteriaceae Producing Carbapenem-Hydrolyzing Enzymes
Falagas, M. E., Karageorgopoulos, D. E., & Nordmann, P. (2011) · Future Microbiology · doi:10.2217/fmb.11.49 · Cited by 167
The inhibition of class C β-lactamases by boronic acids
Beesley, T., Gascoyne, N., Knott-Hunziker, V, Petursson, S., Waley, S. G., Jaurin, B., & Grundström, T. (1983) · Biochemical Journal · doi:10.1042/bj2090229 · Cited by 159
Garcia-Saez, I., Hopkins, J., Papamicaël, C. A., Franceschini, N., Amicosante, G., Rossolini, G. M., Galleni, M., Frère, J., & Dideberg, O. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301062200 · Cited by 149
Metallo-β-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
Maltezou, H. C. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.09.003 · Cited by 147
Hirsch, E. B., Ledesma, K. R., Chang, K., Schwartz, M. S., Motyl, M. R., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05927-11 · Cited by 145
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
The FDA Reboot of Antibiotic Development
Shlaes, D. M., Sahm, D., Opiela, C., & Spellberg, B. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01277-13 · Cited by 143
Structure-Based Enhancement of Boronic Acid-Based Inhibitors of AmpC β-Lactamase
Weston, G. S., Blázquez, J., Baquero, F., & Shoichet, B. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980343w · Cited by 142
Reversible inhibitors of penicillinases
Kiener, P. A., & Waley, S. G. (1978) · Biochemical Journal · doi:10.1042/bj1690197 · Cited by 139
Endimiani, A., Choudhary, Y., & Bonomo, R. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00641-09 · Cited by 133
Self-citationNew β‐lactam–β‐lactamase inhibitor combinations in clinical development
Shlaes, D. M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12010 · Cited by 130
Nanomolar Inhibitors of AmpC β-Lactamase
Morandi, F., Caselli, E., Morandi, S., Focia, P. J., Blázquez, J., Shoichet, B. K., & Prati, F. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0288338 · Cited by 130
Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols
Liénard, B. M. R., Garau, G., Horsfall, L., Karsisiotis, A. I., Damblon, C., Lassaux, P., Papamicaël, C. A., Roberts, G. C. K., Galleni, M., Dideberg, O., et al. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b802311e · Cited by 129
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Mushtaq, S., Warner, M., & Livermore, D. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq306 · Cited by 129
Héritier, C., Poirel, L., Aubert, D., & Nordmann, P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.268-273.2003 · Cited by 129
A Concise Synthesis of a β-Lactamase Inhibitor
Mangion, I. K., Ruck, R. T., Rivera, N. R., Huffman, M. A., & Shevlin, M. (2011) · Organic Letters · doi:10.1021/ol202195n · Cited by 125
Virtual Screening against Metalloenzymes for Inhibitors and Substrates
Irwin, J. J., Raushel, F. M., & Shoichet, B. K. (2005) · Biochemistry · doi:10.1021/bi050801k · Cited by 121
Livermore, D. M., Mushtaq, S., Warner, M., Miossec, C., & Woodford, N. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn320 · Cited by 120
Crandon, J. L., Schuck, V., Banevicius, M. A., Beaudoin, M., Nichols, W. W., Tanudra, M. A., & Nicolau, D. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00851-12 · Cited by 118
Investigational Antimicrobial Agents of 2013
Pucci, M. J., & Bush, K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00033-13 · Cited by 113
Infectious Diseases Society of America (IDSA) (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis688 · Cited by 103
Levasseur, P., Girard, A.-M., Claudon, M., Goossens, H., Black, M. T., Coleman, K., & Miossec, C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06064-11 · Cited by 102
Improving known classes of antibiotics: an optimistic approach for the future
Bush, K. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.003 · Cited by 100
Livermore, D. M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt118 · Cited by 90
Structure-based design of a potent transition state analogue for TEM-1 β-lactamase
Strynadka, N. C. J., Martin, R., Jensen, S. E., Gold, M. H., & Jones, J. B. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-688 · Cited by 89
Mushtaq, S., Warner, M., Williams, G. B., Critchley, I. A., & Livermore, D. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq161 · Cited by 86
Aoki, N., Ishii, Y., Tateda, K., Saga, T., Kimura, S., Kikuchi, Y., Kobayashi, T., Tanabe, Y., Tsukada, H., Gejyo, F., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00511-10 · Cited by 84
Lagacé-Wiens, P. R. S., Tailor, F., Simner, P. J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01722-10 · Cited by 80
Yoshizumi, A., Ishii, Y., Kimura, S., Saga, T., Harada, S., Yamaguchi, K., Kazuhiro, T., Livermore, D. M., Woodford, N., & Livermore, D. M. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0528-y · Cited by 78
Endimiani, A., Hujer, K. M., Hujer, A. M., Pulse, M., Weiss, W. J., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-10 · Cited by 77
Self-citationFragment-guided design of subnanomolar β-lactamase inhibitors active in vivo
Eidam, O., Romagnoli, C., Dalmasso, G., Barelier, S., Caselli, E., Bonnet, R., Shoichet, B. K., & Prati, F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208337109 · Cited by 77
Castanheira, M., Sader, H. S., Farrell, D. J., Mendes, R. E., & Jones, R. N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00817-12 · Cited by 74
Eidam, O., Romagnoli, C., Caselli, E., Babaoglu, K., Pohlhaus, D. T., Karpiak, J. D., Bonnet, R., Shoichet, B. K., & Prati, F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101015z · Cited by 71
NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis
Xu, H., Hazra, S., & Blanchard, J. S. (2012) · Biochemistry · doi:10.1021/bi300508r · Cited by 70
Bou, G., Santillana, E., Sheri, A., Beceiro, A., Sampson, J. M., Kalp, M., Bethel, C. R., Distler, A. M., Drawz, S. M., Pagadala, S. R. R., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104092z · Cited by 68
Self-citationIntegration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model
Flückiger, U. M., Segessenmann, C., & Gerber, A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1905 · Cited by 62
Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
Bhagunde, P. R., Chang, K., Hirsch, E. B., Ledesma, K. R., Nikolaou, M., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06113-11 · Cited by 60
Evolving Carbapenemases: Can Medicinal Chemists Advance One Step Ahead of the Coming Storm?
Oelschlaeger, P., Ai, N., DuPrez, K. T., Welsh, W. J., & TONEY, J. H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9012938 · Cited by 59
Clawing back: broadening the notion of metal chelators in medicine
Franz, K. J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.12.021 · Cited by 58
Probing chelation motifs in HIV integrase inhibitors
Agrawal, A., DeSoto, J., Fullagar, J. L., Maddali, K., Rostami, S., Richman, D. D., Pommier, Y. G., & Cohen, S. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112389109 · Cited by 57
Johnson, J. W., Gretes, M. C., Goodfellow, V. J., Marrone, L., Heynen, M., Strynadka, N. C. J., & Dmitrienko, G. I. (2010) · Journal of the American Chemical Society · doi:10.1021/ja9086374 · Cited by 52
Ke, W., Bethel, C. R., Papp‐Wallace, K. M., Pagadala, S. R. R., Nottingham, M., Fernández, D., Buynak, J. D., Bonomo, R. A., & van den Akker, F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06099-11 · Cited by 51
Self-citationDrawz, S. M., Taracila, M. A., Caselli, E., Prati, F., & Bonomo, R. A. (2011) · Protein Science · doi:10.1002/pro.612 · Cited by 51
Self-citationβ-Lactamase inhibitors: a review of the patent literature (2010 – 2013)
Buynak, J. D. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.831071 · Cited by 48
Systematic Analysis of Metallo-β-Lactamases Using an Automated Database
Widmann, M., Pleiss, J., & Oelschlaeger, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00255-12 · Cited by 48
Drawz, S. M., Babić, M. S., Bethel, C. R., Taracila, M., Distler, A. M., Ori, C., Caselli, E., Prati, F., & Bonomo, R. A. (2009) · Biochemistry · doi:10.1021/bi9015988 · Cited by 46
Self-citationWinkler, M., Rodkey, E. A., Taracila, M. A., Drawz, S. M., Bethel, C. R., Papp‐Wallace, K. M., Smith, K. M., Xu, Y., Dwulit‐Smith, J. R., Romagnoli, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301490d · Cited by 45
Self-citationGoldstein, E. J. C., Citron, D. M., Tyrrell, K. L., & Merriam, C. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-12 · Cited by 45
Penicillin Sulfone Inhibitors of Class D β-Lactamases
Drawz, S. M., Bethel, C. R., Doppalapudi, V. R., Sheri, A., Pagadala, S. R. R., Hujer, A. M., Skalweit, M. J., Anderson, V. E., Chen, S. G., Buynak, J. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00743-09 · Cited by 44
Self-citationKe, W., Sampson, J. M., Ori, C., Prati, F., Drawz, S. M., Bethel, C. R., Bonomo, R. A., & van den Akker, F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00930-10 · Cited by 31
Self-citationDubreuil, L. J., Mahieux, S., Neut, C., Miossec, C., & Pace, J. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.02.013 · Cited by 26
Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone
Papp‐Wallace, K. M., Bethel, C. R., Gootz, T. D., Shang, W., Stroh, J. G., Lau, W., McLeod, D., Price, L. M., Marfat, A., Distler, A. M., et al. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.015 · Cited by 18
Self-citationEnzymology of Bacterial Resistance
Fisher, J. F., & Mobashery, S. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00161-1 · Cited by 15
Cited by
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., & Zong, Z. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-18 · Cited by 700
Update on the antibiotic resistance crisis
Rossolini, G. M., Arena, F., Pecile, P., & Pollini, S. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.09.006 · Cited by 695
β-lactam antibiotics: An overview from a medicinal chemistry perspective
Lima, L. M., Silva, B. N. M. D., Barbosa, G., & Barreiro, E. J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112829 · Cited by 642
Next-generation approaches to understand and combat the antibiotic resistome
Crofts, T. S., Gasparrini, A. J., & Dantas, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.28 · Cited by 535
Metadata
- Authors
- Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-04
- Volume
- 58
- Issue
- 4
- Pages
- 1835-1846
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2139911027
- Cited by
- 286
- References
- 99
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.